Evolving therapeutic goals in ulcerative colitis: towards disease clearance
- 1 January 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Reviews Gastroenterology & Hepatology
- Vol. 17 (1), 1-2
- https://doi.org/10.1038/s41575-019-0211-1
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2019
- A Treat-to-Target Update in Ulcerative Colitis: A Systematic ReviewThe American Journal of Gastroenterology, 2019
- Clinical Goals and Barriers to Effective Psoriasis CareDermatology and Therapy, 2018
- Ixekizumab: A Review of Its Use for the Management of Moderate to Severe Plaque PsoriasisAnnals of Pharmacotherapy, 2018
- Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative ColitisDigestive Diseases and Sciences, 2018
- Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumabJournal of Dermatological Treatment, 2017
- Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UCGut, 2016
- Clinical Remission As Defined by the Mayo ScoreInflammatory Bowel Diseases, 2015
- Histologic Remission: The Ultimate Therapeutic Goal in Ulcerative Colitis?Clinical Gastroenterology and Hepatology, 2013
- Monitoring inflammatory bowel disease activity: Clinical activity is judged to be more relevant than endoscopic severity or biomarkersJournal of Crohn's and Colitis, 2012